Observational studies conducted in real-world settings revealed a notable trend towards a reduced fracture risk associated with GLP-1ra, or DPP-4i utilization, although this relation didn’t statistically significant ( 28 ).
← all excerpts
Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.
1
—
—